At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 117 enrolled
Drug / intervention
Tirzepatide +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Tirzepatide on α and β Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating Tirzepatide, Semaglutide, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 117 participants across 2 sites.
Detailed Summary
This is a study for participants with type 2 diabetes mellitus. The main purpose of this study is to learn more about how tirzepatide, semaglutide and placebo affect the body's ability to respond to blood sugar levels after a meal. The study will last up to 40 weeks, including a 28-week treatment period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartJun 2019
Primary CompletionApr 2021
TodayJul 2026
First PostedMay 15, 2019
Enrollment StartJun 28, 2019
Primary CompletionApr 8, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.1 years ago
Interventions
Tirzepatidedrug
Administered SC
Semaglutidedrug
Administered SC
Placebodrug
Administered SC